Cocrystal Pharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sam Lee
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 19805 North Creek Parkway Bothell WA United States of America 98011
- IPO Date
- Feb 22, 2012
- CIK
- 0001412486
- Website
- cocrystalpharma.com
- Similar Companies
- Business
- Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics targeting the replication process of influenza viruses, coronaviruses including SARS-CoV-2, noroviruses, and hepatitis C virus; the company employs a proprietary structure-based drug discovery platform leveraging Nobel Prize-winning expertise to create broad-spectrum small-molecule antivirals that bind conserved viral enzyme regions for efficacy against mutations and reduced side effects. Headquartered in Bothell, Washington, and founded in 2007, Cocrystal focuses on serious and chronic viral diseases with significant unmet needs, operating primarily in the United States with clinical trials conducted in Australia and the United Kingdom. Its lead product candidates include CC-42344, an oral PB2 inhibitor in Phase 2 for seasonal and pandemic influenza A including resistant and H5N1 strains, an inhaled formulation of CC-42344 completed through preclinical toxicology for influenza A prophylaxis and treatment, CDI-988 an oral pan-viral protease inhibitor in Phase 1 with FDA IND clearance for a Phase 1b norovirus challenge study as both preventive and therapeutic targeting norovirus and coronaviruses, CDI-988 also demonstrating activity against common human coronaviruses rhinoviruses and respiratory enteroviruses, plus early-stage programs in influenza A/B replication inhibitors, norovirus replication inhibitors, and pan-viral respiratory inhibitors. Recent developments include completion of the CC-42344 Phase 2a human challenge study in November 2025 with favorable safety and no serious adverse events though efficacy not reported due to trial conduct issues, FDA clearance in September 2025 for the CDI-988 norovirus Phase 1b challenge study with enrollment planned for Q1 2026, a $500,000 NIH SBIR Phase I award in October 2025 to advance influenza A/B polymerase inhibitors, a $1.03 million private placement in October 2025 led by directors and management including Chairman Phillip Frost with potential additional $1.83 million from warrants, and a $4.7 million registered direct offering in September 2025 with up to $8.3 million more from warrants; earlier an ongoing Merck collaboration since 2019 provides milestone funding for influenza programs, favorable Phase 1 safety data for CDI-988 across all doses including high-dose 1200 mg presented in August 2025, and superiority of CDI-988 against prevalent GII.17 norovirus strains shown in April 2025.
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma (COCP) Expected to Announce Earnings on Monday
Cocrystal Pharma (NASDAQ:COCP) Shares Up 2% – Should You Buy?
First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
Insider Buying: Cocrystal Pharma (NASDAQ:COCP) Director Buys $19,400.00 in Stock
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules